Casdin Capital, Llc Purchases 100,000 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGSGet Free Report) Director Casdin Capital, Llc bought 100,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were acquired at an average cost of $20.82 per share, with a total value of $2,082,000.00. Following the completion of the purchase, the director now owns 3,063,509 shares of the company’s stock, valued at $63,782,257.38. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Casdin Capital, Llc also recently made the following trade(s):

  • On Tuesday, May 28th, Casdin Capital, Llc purchased 18,304 shares of GeneDx stock. The stock was bought at an average cost of $20.61 per share, for a total transaction of $377,245.44.
  • On Thursday, May 23rd, Casdin Capital, Llc acquired 7,500 shares of GeneDx stock. The shares were bought at an average cost of $19.59 per share, with a total value of $146,925.00.
  • On Monday, May 13th, Casdin Capital, Llc bought 50,000 shares of GeneDx stock. The shares were bought at an average cost of $23.31 per share, for a total transaction of $1,165,500.00.

GeneDx Trading Down 3.8 %

NASDAQ:WGS opened at $26.23 on Friday. The stock’s 50-day moving average is $16.36 and its two-hundred day moving average is $8.72. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.22 and a quick ratio of 2.99. The stock has a market cap of $685.13 million, a PE ratio of -5.06 and a beta of 2.21. GeneDx Holdings Corp. has a fifty-two week low of $1.16 and a fifty-two week high of $28.54.

GeneDx (NASDAQ:WGSGet Free Report) last announced its quarterly earnings data on Monday, April 29th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.35. GeneDx had a negative net margin of 60.86% and a negative return on equity of 36.23%. The firm had revenue of $62.42 million for the quarter, compared to the consensus estimate of $49.80 million.

Analyst Ratings Changes

WGS has been the topic of several recent analyst reports. Jefferies Financial Group initiated coverage on GeneDx in a report on Monday. They set a “hold” rating and a $21.00 price objective on the stock. BTIG Research boosted their price target on shares of GeneDx from $15.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. TD Cowen raised their price objective on shares of GeneDx from $14.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Finally, The Goldman Sachs Group boosted their target price on shares of GeneDx to $11.00 and gave the company a “neutral” rating in a research note on Monday, April 15th.

Check Out Our Latest Report on GeneDx

Institutional Trading of GeneDx

A number of institutional investors have recently bought and sold shares of the company. Decheng Capital LLC purchased a new stake in shares of GeneDx during the 4th quarter worth about $285,000. HighTower Advisors LLC raised its position in GeneDx by 14.1% during the third quarter. HighTower Advisors LLC now owns 237,948 shares of the company’s stock valued at $865,000 after acquiring an additional 29,361 shares in the last quarter. Oracle Investment Management Inc. lifted its stake in GeneDx by 14.9% in the third quarter. Oracle Investment Management Inc. now owns 994,580 shares of the company’s stock valued at $3,620,000 after acquiring an additional 128,731 shares during the last quarter. Pathstone Family Office LLC grew its position in GeneDx by 262.2% in the third quarter. Pathstone Family Office LLC now owns 54,327 shares of the company’s stock worth $198,000 after acquiring an additional 39,327 shares in the last quarter. Finally, Thompson Davis & CO. Inc. increased its stake in shares of GeneDx by 99.4% during the 4th quarter. Thompson Davis & CO. Inc. now owns 19,944 shares of the company’s stock worth $55,000 after purchasing an additional 9,944 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Company Profile

(Get Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

See Also

Insider Buying and Selling by Quarter for GeneDx (NASDAQ:WGS)

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.